Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Charles Ryan on Prescribing Preferences

March 13th 2014

Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.

Brisk Walking May Lower Prostate Cancer Aggressiveness

March 11th 2014

Brisk walking helps normalize the shape of vessels in prostate cancer tumors, which may make the tumors less aggressive and more responsive to anti-cancer therapies

Dr. Galsky on Biomarkers for Satraplatin in mCRPC

March 4th 2014

Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with mCRPC.

Sipuleucel-T Soon Available to Patients in Europe and Beyond

March 3rd 2014

An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.

Dr. Yu Discusses the Utility of GTx-758 in mCRPC

February 24th 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the utility of GTx-758 in mCRPC.

Adding Epidural to Anesthesia During Prostatectomy May Improve Long-Term Outcomes in Men With PC

February 24th 2014

Long-term outcomes for patients with prostate cancer following radical prostatectomy were better when a spinal or epidural pain block was added to general anesthesia during the surgery.

Dr. McKay Discusses Dutasteride in Prostate Cancer

February 20th 2014

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, explains the mechanism of action of dutasteride and its role in a phase II trial in which abiraterone acetate was combined with dutasteride in men with metastatic castration-resistant prostate cancer

Sawyers' Scientific Approach Paved Way for Discoveries in Two Tumor Types

February 10th 2014

During his undergraduate years at Princeton University, Charles L. Sawyers, MD, studied history. Now, well into his career as a physician and translational scientist, Sawyers is busy making it.

Dr. Yu Discusses Optimal Testosterone Suppression

February 6th 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

Adding Chemotherapy to ADT Improves Survival in Metastatic Prostate Cancer

February 5th 2014

Administering chemotherapy concurrently with androgen deprivation therapy (ADT), rather than saving cytotoxic treatment until after progression, improves overall survival for men with hormone-sensitive metastatic prostate cancer

Robert McCormack Explains the CellSearch CTC Test

February 5th 2014

Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, explains the circulating tumor cell test CellSearch.

Dr. Beer on the Implications of the PREVAIL Study

February 3rd 2014

Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

Dr. Fosså on Radiotherapy/ Antiandrogen Therapy

February 3rd 2014

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

Dr. Oh on Validating Gene Signatures in mCRPC

February 1st 2014

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses validating a whole-blood RNA prognostic signature in mCRPC.

Role of Corticosteroids Unclear for Men With mCRPC

January 31st 2014

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.

Three Studies Provide Insights About Combining/Sequencing Abiraterone

January 31st 2014

Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate

Follow-up Confirms Safety of Radium-223 in mCRPC

January 31st 2014

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.

Dr. Gomella Discusses New Data on Sipuleucel-T

January 31st 2014

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

Dr. Neal Shore Discusses ODM-201 in CRPC

January 30th 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.

Dr. Tagawa on Abiraterone Plus Docetaxel in mCRPC

January 30th 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.

NEXT PAGE
PREVIOUS PAGE